Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.63 |
| ▸ | S1PR3 | Q99500 | 15/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212226 | 1.00 | S1PR1 (0.63) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3220262 | 1.00 | S1PR1 (0.63) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3220471 | 0.93 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3211856 | 0.93 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3211831 | 0.93 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3210591 | 0.91 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3218817 | 0.91 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3210554 | 0.91 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL3220732 | 0.90 | S1PR1 (0.54) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL3215376 | 0.90 | S1PR1 (0.54) | S1PR1S1PR3MAP4K4PRKCDMINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-2069336-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | S1PR1 96/4885S1PR3 102/4885MAP4K4 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.